Sino Biological,Inc. (SHE:301047)
China · Delayed Price · Currency is CNY 83.58
+13.93 (20.00%)
At close: Aug 4, 2026
Sino Biological,Inc. Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 10,166 | 8,223 | 7,523 | 10,646 | 12,876 | 23,508 | |
Market Cap Growth | 14.68% | 9.30% | -29.33% | -17.32% | -45.23% | - |
Enterprise Value | 6,958 | 5,013 | 3,684 | 5,947 | 6,915 | 17,218 |
Last Close Price | 83.58 | 66.44 | 56.80 | 73.69 | 87.29 | 154.98 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 64.65 | 55.66 | 61.70 | 40.93 | 42.50 | 32.65 |
Forward PE | - | 52.81 | 42.22 | 34.41 | 38.78 | 20.76 |
PS Ratio | 13.97 | 11.75 | 12.26 | 16.47 | 22.41 | 24.35 |
PB Ratio | 1.90 | 1.55 | 1.30 | 1.67 | 2.02 | 3.48 |
P/TBV Ratio | 2.02 | 1.65 | 1.38 | 1.67 | 2.02 | 3.48 |
P/FCF Ratio | 165.64 | 182.15 | 171.82 | - | 137.95 | 39.53 |
P/OCF Ratio | 57.50 | 56.25 | 66.15 | 33.01 | 51.63 | 36.58 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 9.56 | 7.17 | 6.00 | 9.20 | 12.04 | 17.84 |
EV/EBITDA Ratio | 34.72 | 32.27 | 38.90 | 32.67 | 31.25 | 24.29 |
EV/EBIT Ratio | 63.54 | 55.57 | 125.79 | 43.80 | 33.98 | 24.72 |
EV/FCF Ratio | 113.36 | 111.05 | 84.15 | - | 74.09 | 28.95 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Debt / EBITDA Ratio | 0.23 | 0.30 | 0.56 | 0.42 | 0.29 | 0.07 |
Debt / FCF Ratio | 0.76 | 1.19 | 1.54 | - | 0.76 | 0.08 |
Net Debt / Equity Ratio | -0.60 | -0.60 | -0.67 | -0.75 | -0.90 | -0.96 |
Net Debt / EBITDA Ratio | -18.38 | -20.40 | -40.98 | -26.17 | -25.90 | -9.12 |
Net Debt / FCF Ratio | -52.28 | -70.19 | -88.66 | 6.61 | -61.41 | -10.87 |
Asset Turnover | 0.13 | 0.12 | 0.10 | 0.10 | 0.09 | 0.23 |
Inventory Turnover | 2.72 | 2.65 | 2.92 | 2.52 | 2.63 | 3.54 |
Quick Ratio | 25.86 | 22.41 | 20.86 | 36.64 | 47.60 | 67.82 |
Current Ratio | 26.66 | 23.03 | 21.30 | 37.17 | 48.12 | 68.30 |
Return on Equity (ROE) | 2.83% | 2.67% | 2.01% | 4.08% | 4.62% | 17.89% |
Return on Assets (ROA) | 1.18% | 0.97% | 0.29% | 1.29% | 1.89% | 10.42% |
Return on Invested Capital (ROIC) | 4.02% | 3.68% | 1.45% | 10.95% | 38.86% | 258.62% |
Return on Capital Employed (ROCE) | 2.00% | 1.70% | 0.50% | 2.10% | 3.20% | 10.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 1.55% | 1.80% | 1.62% | 2.44% | 2.35% | 3.06% |
FCF Yield | 0.60% | 0.55% | 0.58% | -6.77% | 0.73% | 2.53% |
Dividend Yield | 7.47% | 7.83% | 1.76% | 2.71% | 2.29% | 3.40% |
Payout Ratio | 386.77% | 411.67% | 209.57% | 99.33% | 224.45% | - |
Buyback Yield / Dilution | 3.51% | 4.93% | 0.97% | -13.44% | -5.79% | -11.11% |
Total Shareholder Return | 11.21% | 12.76% | 2.73% | -10.72% | -3.50% | -7.72% |